Evolocumab and clinical outcomes in patients with cardiovascular disease
- PMID: 28504611
- DOI: 10.1177/0004563217705053
Evolocumab and clinical outcomes in patients with cardiovascular disease
Comment on
-
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17. N Engl J Med. 2017. PMID: 28304224 Clinical Trial.
Similar articles
-
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.N Engl J Med. 2015 Apr 16;372(16):1500-9. doi: 10.1056/NEJMoa1500858. Epub 2015 Mar 15. N Engl J Med. 2015. PMID: 25773607 Clinical Trial.
-
Evolocumab in Patients with Cardiovascular Disease.N Engl J Med. 2017 Aug 24;377(8):787. doi: 10.1056/NEJMc1708587. N Engl J Med. 2017. PMID: 28834473 No abstract available.
-
Evolocumab in Patients with Cardiovascular Disease.N Engl J Med. 2017 Aug 24;377(8):786. doi: 10.1056/NEJMc1708587. N Engl J Med. 2017. PMID: 28834472 No abstract available.
-
Evolocumab (Repatha)--a second PCSK9 inhibitor to lower LDL-Cholesterol.Med Lett Drugs Ther. 2015 Oct 12;57(1479):140-1. Med Lett Drugs Ther. 2015. PMID: 26445204 Review.
-
Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction.Vasc Health Risk Manag. 2016 Apr 19;12:163-9. doi: 10.2147/VHRM.S82387. eCollection 2016. Vasc Health Risk Manag. 2016. PMID: 27143910 Free PMC article. Review.
Cited by
-
New Insights into Cardiovascular Diseases Treatment Based on Molecular Targets.Int J Mol Sci. 2023 Nov 24;24(23):16735. doi: 10.3390/ijms242316735. Int J Mol Sci. 2023. PMID: 38069058 Free PMC article. Review.
-
The Future of Lipid-lowering Therapy.J Clin Med. 2019 Jul 23;8(7):1085. doi: 10.3390/jcm8071085. J Clin Med. 2019. PMID: 31340607 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical